Diazaheterobicyclic Compounds for Selective TASK Channel Blockade
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for breathing disorders such as obstructive sleep apnea, central sleep apnea, and snoring lack effective and selective blockers for TASK-1 and TASK-3 channels, which are crucial for regulating breathing and have implications in various diseases beyond respiratory issues.
Innovation Solution
Development of (imidazo[1,2-a]pyridin-3-yl)methyl-substituted diazaheterobicyclic compounds that act as potent and selective blockers of TASK-1 and TASK-3 channels, capable of stabilizing upper airways and modulating cellular responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for breathing disorders are used, then existing therapeutic options are available, but effective and selective blockers for TASK-1 and TASK-3 channels are lacking
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of compounds to achieve selective blockade of TASK-1 and TASK-3 channels. The invention introduces specific molecular parameters (substituted diazaheterobicyclic structures with imidazo[1,2-a]pyridin-3-yl)methyl groups) that optimize binding affinity and selectivity for these channels, thereby improving treatment effectiveness while maintaining channel selectivity
Solution Approach 2:
The patent segments the therapeutic approach by developing compounds with specific structural divisions: the diazaheterobicyclic core structure is separated and optimized independently, then combined with the (imidazo[1,2-a]pyridin-3-yl)methyl substituent. This segmentation allows independent optimization of each structural element to achieve both effectiveness and selectivity for TASK channels
2Reliability
If TASK-1 and TASK-3 channels are blocked, then breathing disorders can be treated, but potential side effects in other systems may occur
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features that confer selective action on TASK-1 and TASK-3 channels while sparing other potassium channel families. The substituted diazaheterobicyclic structure with its specific spatial arrangement and electronic properties creates localized interaction with TASK channel binding sites, enabling effective treatment with minimized off-target effects
Data Source
AI summary
The present invention relates to novel (imidazo[1,2-a]pyridine-3-yl)methyl-substituted diazahetero-bicyclic compounds, to methods for preparing same, to their use alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for producing drugs for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnea and snoring. The present invention further relates to a method for detecting a compound having TASK-1 and/or TASK-3 blocking properties.